We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Radcal IBA  Group

Download Mobile App




Warning on Faulty Implanted Defibrillators

By HospiMedica staff writers
Posted on 29 Jun 2005
Certain implantable cardiac defibrillators (ICDs) and cardiac resynchronization therapy (CRT) devices develop an internal short circuit without warning, resulting in failure to deliver a shock when needed. More...
The manufacturer, Guidant Corp. (Indianapolis, IN, USA), is advising doctors worldwide of this development so they can decide how best to treat their patients.

The devices involved are the Ventak Prizm 2DR (model 1861) ICDs manufactured on or before April 16, 2002; the Contak Renewal (model H135) and Contak Renewal 2 (model H155), manufactured on or before August 26, 2004; and the Ventak Prizm AVT, Vitality AVT, Renewal 3AVT, and Renewal 4 AVT ICSs (all series).

The Prizm 2 and Renewal devices are subject to failures that result in the inability to deliver an electric shock during episodes of arrhythmia, which could lead to a serious, life-threatening event for a patient. Twenty-eight reports of failure have been reported worldwide in the Ventak Prizm 2 DR devices, including one death. Fifteen reports of failure mode have been confirmed in the Contak Renewal devices. Two deaths suspected to be associated with this malfunction have been reported to the U.S. Food and Drug Administration (FDA, Washington, DC, USA; www.fda.gov). Guidant recommends that doctors of patients with these devices should continue with normal follow-up visits at three-month intervals. If a decision is made to replace a device, Guidant will provide a replacement at no charge.

In addition, the company's Ventak Prizm AVT, Vitality AVT, Renewal 3 AVT, and Renewal 4 AVT devices are subject to a memory error, which may affect available therapy. Guidant is recommending a programming change that can reduce the risk of this happening, a change that can be implemented at the next office visit a patient makes.

The FDA is considering this action of Guidant as a recall and is not making any recommendations at this time on whether individual patients who have one of the devices should have it removed and replaced. That is a decision that should be made by patients in consultation with their doctors. If patients feel an electrical shock from their device or hear an audible "beeping,” they should immediately contact their doctor.




Related Links:
Guidant

Platinum Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Gold Member
Temperature Monitor
ThermoScan Temperature Monitoring Unit
Radiology System
Riviera SPV AT
Infant Incubator
OKM 801
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: Professor Bumsoo Han and postdoctoral researcher Sae Rome Choi of Illinois co-authored a study on using DNA origami to enhance imaging of dense pancreatic tissue (Photo courtesy of Fred Zwicky/University of Illinois Urbana-Champaign)

DNA Origami Improves Imaging of Dense Pancreatic Tissue for Cancer Detection and Treatment

One of the challenges of fighting pancreatic cancer is finding ways to penetrate the organ’s dense tissue to define the margins between malignant and normal tissue. Now, a new study uses DNA origami structures... Read more

Patient Care

view channel
Image: The portable biosensor platform uses printed electrochemical sensors for the rapid, selective detection of Staphylococcus aureus (Photo courtesy of AIMPLAS)

Portable Biosensor Platform to Reduce Hospital-Acquired Infections

Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.